Clinical Trials Logo

Clinical Trial Summary

Total hip arthroplasty (THA) and total knee arthroplasty (TKA) are procedures successfully applied to manage various end-stage chronic hip and knee diseases, such as osteoarthritis, rheumatoid arthritis, and femoral head avascular necrosis, as well as acute conditions, such as the neck of femur fractures, with excellent long-term functional outcomes. One of the devastating complications after such a procedure is periprosthetic joint infection (PJI). Various precautions are proposed to guard against such complications; one is the administration of perioperative antibiotics. However, injudicious or misuse of antibiotics could lead to the emergence of antimicrobial resistance, further complicating this matter. This is why various scientific and research organizations have proposed guidelines and a consensus for proper antibiotic use in perioperative THA and TKA surgery. Antibiotic prophylaxis during primary THA and TKA can reduce the risk of PJI and surgical site infections. However, there is a lack of consensus on the optimal dosages and duration of prophylaxis, and guidelines vary among institutions. Alternatives such as extended oral antibiotic prophylaxis and different antibiotic regimens are being explored. International research is needed to establish best practices and determine the potential risks of antibiotic prophylaxis during primary THA and TKA. Unfortunately, the investigators are unaware of such guidelines proposed by any Egyptian health authority to guide and control the proper utilization of antibiotics during orthoapedic practice in general and joint replacement surgeries (THA and TKA) in particular.


Clinical Trial Description

This study will be an Online-based questionnaire investigating surgeons' perspectives on antibiotics utilization during primary total hip and knee arthroplasty surgeries and investigate their thoughts about the necessity for developing local guidelines. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06451224
Study type Observational
Source South Valley University
Contact Ahmed A. Khalifa, MD,FRCS
Phone 00201224466151
Email ahmed_adel0391@med.svu.edu.eg
Status Not yet recruiting
Phase
Start date June 15, 2024
Completion date July 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05604157 - Ancef Dosage in Knee Arthroplasty : Tourniquet Clinical Trial N/A
Not yet recruiting NCT05902221 - Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections Phase 3
Enrolling by invitation NCT04297592 - Antibiotic Prophylaxis in High-Risk Arthroplasty Patients Phase 4
Recruiting NCT04620395 - Percutaneous Punch Biopsy for Diagnosis of Septic and Aseptic Prosthetic Joint Failure N/A